Cardiol Therapeutics (CRDL) Income from Continuing Operations (2020 - 2026)
Cardiol Therapeutics (CRDL) posted Income from Continuing Operations of 6931880.35 for Q1 2026, down 21.58% on a QoQ basis from 5701330.13 in Q1 2025, and down 21.58% year-over-year from 8839830.89 in Q1 2025.
Cardiol Therapeutics (CRDL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Cardiol Therapeutics' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 6931880.35 for Q1 2026.
- Quarterly Income from Continuing Operations fell 21.58% year-over-year to 6931880.35 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24972549.44 (up 10.42% YoY) and the FY2025 annual result came in at 24086852.95, up 13.91% from the prior year.
- Income from Continuing Operations was 6931880.35 for Q1 2026 at Cardiol Therapeutics, down from 5701330.13 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5701330.13 in Q1 2025 and bottomed at 9837989.19 in Q3 2022.
- A 4-year average of 7081763.99 and a median of 6931880.35 in 2026 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 39.64% in 2022, while the deepest fall reached 36.24% in 2022.
- Cardiol Therapeutics' Income from Continuing Operations stood at 6381515.36 in 2022, then grew by 6.64% to 5957823.61 in 2024, then advanced by 4.31% to 5701330.13 in 2025, then slipped by 21.58% to 6931880.35 in 2026.
- Business Quant data shows CRDL's Income from Continuing Operations at 6931880.35 in Q1 2026, 5701330.13 in Q1 2025, and 5957823.61 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Cardiol Therapeutics | 134.05 Mn | 134.05 Mn | - | -6.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.93 Mn |
| Mar 31, 2025 | -5.70 Mn |
| Mar 31, 2024 | -5.96 Mn |
| Dec 31, 2022 | -6.38 Mn |
| Sep 30, 2022 | -9.84 Mn |
| Jun 30, 2022 | -7.09 Mn |
| Mar 31, 2022 | -7.67 Mn |
| Dec 31, 2021 | -10.57 Mn |
| Sep 30, 2021 | -8.05 Mn |
| Jun 30, 2021 | -5.20 Mn |
| Mar 31, 2021 | -7.08 Mn |
| Dec 31, 2020 | -7.36 Mn |
| Jun 30, 2020 | -2.57 Mn |